UPDATE 1-EU regulator backs use of GSK's RSV shot in adults aged 50 to 59 Adds background throughout July 26 (Reuters) - The European Union health regulator on Friday recommended expanded use of GSK's GSK.L respiratory syncytial virus (RSV) vaccine in adults aged between 50 and 59. Any recommendation by the European Medicines Agency's Committee for Medicinal Products for Human Use has to be formally approved by the European Commission, which usually follows the regulator's decision.

EU regulator recommends use of GSK's RSV shot in adults aged 50 to 59 July 26 (Reuters) - The European Union health regulator on Friday recommended expanded use of GSK's GSK.L respiratory syncytial virus (RSV) vaccine in adults aged between 50 and 59. Reporting by Prerna Bedi in Bengaluru; Editing by Shounak Dasgupta

BRIEF-EMA Says CHMP Recommended Not Granting Marketing Authorisation For Leqembi (Lecanemab) July 26 (Reuters) - Biogen Inc BIIB.O EMA SAYS CHMP EXTENSIONS OF INDICATION FOR 11 MEDICINES THAT ARE ALREADY AUTHORISED IN THE EU INCLUDING AREXVY EMA SAYS CHMP RECOMMENDED NOT GRANTING MARKETING AUTHORISATION FOR LEQEMBI (LECANEMAB) EMA SAYS CHMP RECOMME

UPDATE 5-AstraZeneca raises profit outlook on strong medicines demand Expects 2024 sales and profit to grow by a mid teens percentage Q2 sales of $12.94 billion beat forecast, core EPS $1.98 in line Shares fell as much as 4% Updates shares in paragraph 4 By Pushkala Aripaka and Maggie Fick July 25 (Reuters) - Anglo-Swedish drugmaker AstraZeneca AZN.L raised its full year sales and profit forecast on Thursday after beating analyst expectations for second-quarter revenue on strong demand for its c

BRIEF-GSK Quebec's Committee On Immunization Recommends Use Of RSV Vaccines For Older Adult Populations At Risk Of Severe Outcomes July 24 (Reuters) - GSK plc GSK.L : GSK: QUEBEC'S COMMITTEE ON IMMUNIZATION RECOMMENDS USE OF RSV VACCINES FOR OLDER ADULT POPULATIONS AT RISK OF SEVERE OUTCOMES Source text for Eikon: ID:nCNWrtMg6a Further company cove